精神科医生集体共识：氯氮平更新。
CONSENSUS BY THE COLLECTIVE OF PSYCHIATRISTS FOR THE CLOZAPINE UPDATE.
机构信息
Department of Medicine, Faculty of Medicine and Health Sciences, University of Barcelona (UB), Institute of Neurosciences (UBNeuro), Barcelona Clínic Schizophrenia Unit (BCSU), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. Center for Biomedical Research in the Mental Health Network (CIBERSAM), Carlos III Health Institute, Madrid, Spain.
Cambridge Psychosis Centre. Cambridgeshire and Peterborough NHS Foundation Trust. Cambridge, UK Department of Psychiatry. The University of Cambridge. UK.
出版信息
Actas Esp Psiquiatr. 2023 May;51(3):141-144. Epub 2023 May 1.
Abstract
Treatment-resistant schizophrenia affects one in three patients with schizophrenia, constituting the most severe group of the disease spectrum.
摘要
治疗抵抗性精神分裂症影响了三分之一的精神分裂症患者，构成了疾病谱中最严重的一组。
相似文献
1
CONSENSUS BY THE COLLECTIVE OF PSYCHIATRISTS FOR THE CLOZAPINE UPDATE.精神科医生集体共识：氯氮平更新。
Actas Esp Psiquiatr. 2023 May;51(3):141-144. Epub 2023 May 1.
2
Iranian psychiatrists' attitude towards clozapine use for patients with treatment-resistant schizophrenia: a nationwide survey.伊朗精神科医生对氯氮平治疗难治性精神分裂症患者的态度：一项全国性调查。
BMC Psychiatry. 2022 Aug 6;22(1):534. doi: 10.1186/s12888-022-04179-5.
3
The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry.越来越多的案例表明氯氮平在精神分裂症治疗中的作用：精神科医生和精神病学的责任。
Curr Opin Psychiatry. 2023 Jul 1;36(4):327-336. doi: 10.1097/YCO.0000000000000871. Epub 2023 May 23.
4
Patient characteristics, burden and pharmacotherapy of treatment-resistant schizophrenia: results from a survey of 204 US psychiatrists.治疗抵抗性精神分裂症患者的特征、负担和药物治疗：来自对 204 名美国精神科医生的调查结果。
BMC Psychiatry. 2019 Nov 14;19(1):362. doi: 10.1186/s12888-019-2318-x.
5
Psychiatrists' attitude towards the use of clozapine in the treatment of refractory schizophrenia: A nationwide survey.精神科医生对氯氮平治疗难治性精神分裂症的态度：一项全国性调查。
Psychiatry Res. 2019 May;275:155-161. doi: 10.1016/j.psychres.2019.03.029. Epub 2019 Mar 19.
6
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.德克萨斯药物算法项目治疗精神分裂症的抗精神病药物算法：2006年更新版。
J Clin Psychiatry. 2007 Nov;68(11):1751-62. doi: 10.4088/jcp.v68n1115.
7
Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.氯氮平联合治疗与增效策略在精神分裂症患者中的应用——精神病治疗反应和抵抗（TRRIP）工作组的国际专家调查建议。
Schizophr Bull. 2020 Dec 1;46(6):1459-1470. doi: 10.1093/schbul/sbaa060.
8
Treatment-Resistant Schizophrenia, Clozapine Resistance, Genetic Associations, and Implications for Precision Psychiatry: A Scoping Review.治疗抵抗性精神分裂症、氯氮平抵抗、遗传关联以及对精准精神病学的影响：范围综述。
Genes (Basel). 2023 Mar 10;14(3):689. doi: 10.3390/genes14030689.
9
A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists.中美精神科医生对氯氮平的态度、舒适度和认知的比较。
Community Ment Health J. 2022 Apr;58(3):517-525. doi: 10.1007/s10597-021-00847-0. Epub 2021 May 29.
10
Psychiatrists' attitude towards and knowledge of clozapine treatment.精神科医生对氯氮平治疗的态度和知识。
J Psychopharmacol. 2010 Jul;24(7):965-71. doi: 10.1177/0269881108100320. Epub 2009 Jan 22.
本文引用的文献
1
Clozapine Optimization: A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group.氯氮平优化：精神病治疗反应和耐药性工作组的德尔菲共识指南。
Schizophr Bull. 2023 Jul 4;49(4):962-972. doi: 10.1093/schbul/sbad030.
2
A clozapine's uncharted voyage: Five years and a pandemic after the end of mandatory haematological notifications to the Spanish medicines agency.氯氮平的未知之旅：在西班牙药品管理局停止强制性血液学通报五年及一场大流行之后。
Rev Psiquiatr Salud Ment (Engl Ed). 2022 Oct-Dec;15(4):293-294. doi: 10.1016/j.rpsmen.2022.04.001.
3
Dried Blood Spot (DBS) as a useful tool to improve clozapine, aripiprazole and paliperidone treatment: From adherence to efficiency.干血斑（DBS）作为改善氯氮平、阿立哌唑和帕利哌酮治疗的有用工具：从依从性到疗效。
Rev Psiquiatr Salud Ment (Engl Ed). 2022 Oct-Dec;15(4):230-237. doi: 10.1016/j.rpsmen.2022.04.002.
4
Antipsychotic-Associated Weight Gain and Clinical Improvement Under Clozapine Treatment.氯氮平治疗相关的抗精神病药引起的体重增加与临床改善。
J Clin Psychopharmacol. 2022;42(1):75-80. doi: 10.1097/JCP.0000000000001483.
5
The Effect of Clozapine on Self-reported Duration of Sleep and Its Interaction With 23 Other Medications: A 5-Year Naturalistic Study.氯氮平对自我报告的睡眠时间的影响及其与其他 23 种药物的相互作用：一项为期 5 年的自然主义研究。
J Clin Psychopharmacol. 2021;41(5):534-539. doi: 10.1097/JCP.0000000000001432.
6
Waiting for Godot or the use of biomarkers in clinical practice.
Rev Psiquiatr Salud Ment (Engl Ed). 2021 Jul-Sep;14(3):123-124. doi: 10.1016/j.rpsmen.2021.07.003.
7
Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.氯氮平联合治疗与增效策略在精神分裂症患者中的应用——精神病治疗反应和抵抗（TRRIP）工作组的国际专家调查建议。
Schizophr Bull. 2020 Dec 1;46(6):1459-1470. doi: 10.1093/schbul/sbaa060.
8
Intra-individual variation of clozapine and norclozapine plasma levels in clinical practice.临床实践中氯氮平与去甲氯氮平血药浓度的个体内变异
Rev Psiquiatr Salud Ment (Engl Ed). 2020 Jan-Mar;13(1):31-35. doi: 10.1016/j.rpsm.2019.03.002. Epub 2019 May 21.
9
Pattern of use of clozapine in Spain. Variability and under-prescription.西班牙氯氮平的使用模式。变异性与处方不足。
Rev Psiquiatr Salud Ment (Engl Ed). 2019 Jul-Sep;12(3):151-162. doi: 10.1016/j.rpsm.2018.02.005. Epub 2018 Apr 7.
10
International trends in clozapine use: a study in 17 countries.国际氯氮平使用趋势：17 个国家的研究。
Acta Psychiatr Scand. 2017 Jul;136(1):37-51. doi: 10.1111/acps.12742. Epub 2017 May 14.
Zotero 插件